右美托咪定杂质6 | 90525-99-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 右美托咪定杂质6
• 英文名称: 2,3,N,N-tetramethylbenzamide
• 英文别名: N,N-dimethyl-2,3-dimethylbenzamide；N,N,2,3-tetramethylbenzamide
• CAS: 90525-99-8
• 化学式: C₁₁H₁₅NO
• mdl: MFCD20355199
• 分子量: 177.246
• InChiKey: KJFNIMLMIUNQSJ-UHFFFAOYSA-N

物化性质

• 沸点：
  320.3±31.0 °C(Predicted)
• 密度：
  0.999±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.363
• 拓扑面积：
  20.3
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  右美托咪定杂质6 在 正丁基锂 、 仲丁基锂 、 二异丙胺 作用下， 以 四氢呋喃 、 正己烷 、 环己烷 为溶剂， 反应 35.5h， 生成 4,5-dimethyl-3-phenylisoquinolin-1-one
  参考文献：
  名称：

  [EN] TANKYRASE INHIBITORS
  [FR] INHIBITEURS DE TANKYRASE

  摘要：

  本发明涉及一种具有式I的化合物，其中X为C(R6)或N，Y为C或N，环A、环B、R1和R2具有本文中定义的含义，前提是当环B为碳环时，X为C(R6)；或其药学上可接受的盐或溶剂。这些化合物是坦克酶-1和坦克酶-2抑制剂，并可用于治疗多种疾病，包括癌症。

  公开号：

  WO2014087165A1
• 作为产物：
  描述：

  2,3-二甲基苯甲酸 在 氯化亚砜 作用下， 以 二氯甲烷 、 水 为溶剂， 反应 17.0h， 生成 右美托咪定杂质6
  参考文献：
  名称：

  Exploration of the nicotinamide-binding site of the tankyrases, identifying 3-arylisoquinolin-1-ones as potent and selective inhibitors in vitro

  摘要：

  Tankyrases-1 and -2 (TNKS-1 and TNKS-2) have three cellular roles which make them important targets in cancer. Using NAD+ as a substrate, they poly(ADP-ribosyl) ate TRF1 (regulating lengths of telomeres), NuMA (facilitating mitosis) and axin (in wnt/beta-catenin signalling). Using molecular modelling and the structure of the weak inhibitor 5-aminoiso quinolin-1-one, 3-aryl-5-substituted-isoquinolin-1-ones were designed as inhibitors to explore the structure-activity relationships (SARs) for binding and to define the shape of a hydrophobic cavity in the active site. 5-Amino-3-arylisoquinolinones were synthesised by Suzuki-Miyaura coupling of arylboronic acids to 3-bromo-1-methoxy-5-nitro-isoquinoline, reduction and O-demethylation. 3-Aryl-5-methylisoquinolin-1-ones, 3-aryl-5-fluoroisoquinolin-1-ones and 3-aryl-5-methoxyisoquinolin-1-ones were accessed by deprotonation of 3-substituted-N,N,2-trimethylbenzamides and quench with an appropriate benzonitrile. SAR around the isoquinolinone core showed that aryl was required at the 3-position, optimally with a para-substituent. Small meta-substituents were tolerated but groups in the ortho-positions reduced or abolished activity. This was not due to lack of coplanarity of the rings, as shown by the potency of 4,5-dimethyl-3-phenylisoquinolin-1-one. Methyl and methoxy were optimal at the 5-position. SAR was rationalised by modelling and by crystal structures of examples with TNKS-2. The 3-aryl unit was located in a large hydrophobic cavity and the para-substituents projected into a tunnel leading to the exterior. Potency against TNKS-1 paralleled potency against TNKS-2. Most inhibitors were highly selective for TNKSs over PARP-1 and PARP-2. A range of highly potent and selective inhibitors is now available for cellular studies. (C) 2015 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2015.06.061

文献信息

• Substituted triazole derivatives as oxytocin antagonists
  申请人：Brown Daniel Alan

  公开号：US20060160786A1

  公开（公告）日：2006-07-20

  The present invention relates to substituted triazoles of formula (I), uses thereof, processes for the preparation thereof and compositions containing said compounds. These inhibitors have utility in a variety of therapeutic areas including sexual dysfunction.

  本发明涉及公式（I）的取代三唑化合物，其用途，制备方法以及含有该化合物的组合物。这些抑制剂在包括性功能障碍在内的各种治疗领域具有用途。
• Isoquinoline compound and pharmaceutical use thereof
  申请人：Mitsubishi Pharma Corporation

  公开号：US20040248931A1

  公开（公告）日：2004-12-09

  The present invention relates to an isoquinoline compound represented by the following formula (I), an optically active form thereof, a pharmaceutically acceptable salt thereof, a water adduct thereof, a hydrate thereof and a solvate thereof, as well as an agent for the prophylaxis and/or treatment of a disease caused by hyperreactivity of poly(ADP-ribose)polymerase, containing the compound, and a poly(ADP-ribose)polymerase inhibitor containing the compound. In addition, this compound is useful as an agent for the prophylaxis and/or treatment of cerebral infarction, particularly as an agent for the prophylaxis and/or treatment of acute cerebral infarction. Furthermore, this compound is useful as a prophylactic and/or therapeutic agent that improves neurological symptoms associated with cerebral infarction, particularly acute cerebral infarction. 1 wherein the symbols are the same as defined in the description.

  本发明涉及一种异喹啉化合物，其由以下通式(I)表示，包括其光学活性形式、药学上可接受的盐、水合物、水合物和溶剂合物，以及用于预防和/或治疗由聚(ADP-核糖)聚合酶过度反应性引起的疾病的药物组合物，包含该化合物，以及包含该化合物的聚(ADP-核糖)聚合酶抑制剂。此外，该化合物可作为预防和/或治疗脑梗塞，特别是急性脑梗塞的药物。此外，该化合物可作为改善与脑梗塞，特别是急性脑梗塞相关的神经症状的预防和/或治疗药物。其中，符号的定义与说明书中的定义相同。
• FUSED HETEROCYCLIC COMPOUND AND MEDICINAL USE THEREOF
  申请人：Mitsubishi Pharma Corporation

  公开号：EP1396488A1

  公开（公告）日：2004-03-10

  The fused heterocyclic compound of the present invention, which is represented by the formula (I): wherein each symbol is as defined in the specification, an optically active form thereof, a pharmaceutically acceptable salt thereof, a hydrate thereof and a water adduct thereof show poly(ADP-ribose) synthase inhibitory action and are useful as therapeutic drugs for cerebral infarction.

  本发明的融合杂环化合物，其化学式表示为（I）：其中每个符号如规范中定义，其光学活性形式，其药学上可接受的盐，其水合物和水加合物显示聚(ADP-核糖)合酶抑制作用，并可用作治疗脑梗死的药物。
• A novel method for the one-pot conversion of carboxylic acids to N,N-dimethylamides
  作者：Babak Kaboudin、Hamideh Haghighat

  DOI：10.1007/s13738-012-0112-5

  日期：2012.12

  been developed for the preparation of N,N-dimethylamides from carboxylic acids. As described below, treatment of a variety of aromatic carboxylic acids with N,N-dimethylsulfamoyl imidazole or N,N-dimethylsulfamoyl chloride in the presence of a mixture of methanesulfonic acid/phosphorus pentoxide (2:1, v/w) proceeded effectively to afford the corresponding N,N-dimethylamides in moderate to good yields

  已经开发了一种简单，有效和新的方法，用于从羧酸制备N，N-二甲基酰胺。如下所述，治疗多种的芳族羧酸与N，N-二甲基氨磺酰咪唑或N，N-甲磺酸的混合物的存在下二甲基氨磺酰氯/五氧化二磷（2：1，V / W）有效地进行到以中等至良好的收率得到相应的N，N-二甲基酰胺。该方法简便，快速且产率高，可用于从羧酸合成N，N-二甲基酰胺。
• Fused heterocyclic compound and medicinal use thereof
  申请人：——

  公开号：US20040176361A1

  公开（公告）日：2004-09-09

  The fused heterocyclic compound of the present invention, which is represented by the formula (I): 1 wherein each symbol is as defined in the specification, an optically active form thereof, a pharmaceutically acceptable salt thereof, a hydrate thereof and a water adduct thereof show poly(ADP-ribose) synthase inhibitory action and are useful as therapeutic drugs for cerebral infarction.

  本发明的融合杂环化合物，由式(I)表示：1其中每个符号如规范中所定义，其光学活性形式，其药学上可接受的盐，其水合物和水加合物均表现出聚(ADP-核糖)合酶抑制作用，并且可用作治疗脑梗塞的治疗药物。